

# Bits and Pieces: When Missed Information Makes an Impact

Megan Dupont MLS(ASCP)<sup>CM</sup>SBB<sup>CM</sup>













Expanding our organization to meet clinical, cellular and transfusion product and service needs for patients.

Now providing almost one million blood products, over 450,000 laboratory and multi-assay infectious disease tests, and over 12,500 specialty clinical procedures annually to hospitals nationwide.















# **CASE BACKGROUND**

## Here's what we know...

- LB is a 15 year old male trauma victim
- O Pos
- Screening Cells II & III both 2+ (Gel)
- Negative DAT
- Multiply transfused 8 days previously
- Client is requesting antibody identification and 4 units of RBCs to have available for AM surgery













## **OUR WORKUP- ABORH & DAT**

		ABO Group			Rh	Туре		
	Anti-A	Anti-D	Control					
IS	0	0	4+	4+	r	0		
5'RT					1+W	0		
15'RT					2+ <sup>mf*</sup>	0		



\*Hospital reported that the patient is O Pos and had received O Neg RBCs recently

#### **Direct Antiglobulin Test**

Poly	IgG		Saline
(+)	(+ <sup>w</sup> )	(0)	(0)











# **OUR WORKUP - 1ST PANEL**

				Rh			K	ell	Duffy		Kidd			М	NS		Res	ults
		D	C	E	C	e	K	k	Fya	Fyb	Jka	\lambda k <sup>b</sup>	M	N	S	S	5 min RT	PEG IAT
1	$R_1R_1$	+	+	0	0	+	+	0	0	+	0	+	0	+	0	+	0	(0)
2	$R_2R_2$	+	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	(0) 🗸
2	D D			0	0		0		0	0	0	+	We	will	con	ne	0	(0)
3	$R_1R_1$	+	+	U	U	+	0	+	0	"	0	+	bac	k to	this	6	U	(0) 🗸
4	rr	0	0	0	+	+	0	+	0	0	0	+	rea	ctivi	ty!		0	(0)
5	$R_1R_1$	+	+	0	0	+	0	+	0	+	0	+	+	0	+	+	0	(+w)
6	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	+	0	0	+	0	+	0	(0)
7	$R_1R_1$	+	+	0	0	+	0	+	+	0	0	+	0	+	0	+	0	(0)
8	rr	0	0	0	+	+	0	+	+	+	0	+	+	0	+	0	0	(0) 🗸
Auto																	0	(0) 🗸












Not quite what we expected...

What testing methodology was our client using again?













# **CASE BACKGROUND**

## Here's what we know...

- LB is a 15 year old male trauma victim
- O Pos
- Screening Cells II & III both 2+ (Gel)
- Negative DAT
- Patient multiply transfused 8 days previously
- Client is requesting antibody identification and 4 units of RBCs to have available for AM surgery













# OUR WORKUP - 1<sup>ST</sup> PANEL MTS GEL TESTING

		_							_	_	┸					_			
				Rh			K	ell	Du	ıffy	<b>J</b> ki	dd		M	NS			Results	
		X	X	E	X	e	K	)k/	Eya	Fyb	Jkª	lkb	<b>X</b>	X	S	5	5 min RT	PEG IAT	MTS GEL
1	$R_1R_1$	+	+	0	0	+	+	0	0	+	0	+	0	+	0	+	0	(0) 🗸	0
2	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	(0) 🗸	0
3	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	0	0	+	0	+	0	0	0	(0) 🗸	0
4	rr	0	0	0	+	+	0	+	0	0	0	+	+	0	0	+	0	(0) 🗸	0
5	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	0	+	+	0	+	+	0	(+w)	0
6	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	+	0	0	+	0	+	0	(0) 🗸	2+
7	$R_1R_1$	+	+	0	0	+	0	+	+	0	0	+	0	+	0	+	0	(0) 🗸	0
8	rr	0	0	0	+	+	0	+	+	+	0	+	+	0	+	0	0	(0) 🗸	0
Auto																	0	(0) 🗸	0











## **OUR WORKUP-2ND GEL PANEL**

	1			Rh			Ke	<b>11</b>	Du	ffy	-   <sub> </sub>	dd		D.	1NS		
				IXII			, ixe		Du		$\checkmark$				1143		Results
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	D	C	E,	<b>V</b>	е	K	k	Fy	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	М	N	S	S	MTS
		1				\					•						GEL
1	rr	0	0	0	+	+	+	+	0	+	+	0	+	0	+	0	2+
2	rr	0	0	0	+	+	0	+	+	+	+	0	+	0	+	0	2+
3	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	+	0	+	0	+	0	0	+	2+
4	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	+	+	+	0	+	0	0	+	0	+	2+
5	rr	0	0	0	+	+	0	+	+	0	+	+	0	+	0	+	1+ <sup>w</sup>
6	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	+	0	+	+	+	+	+	+	0	+	1+
7	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	+	0	0	+	+	+	+	+	0
8	rr	0	0	0	+	+	+	+	+	0	0	+	+	0	+	0	0













## **ELUSIVE KIDD BLOOD GROUP ANTIBODIES...**

Kay B, Poisson JL, Tuma CW, Shulman IA (2016). Anti-Jk<sup>a</sup> that are detected by solid-phase red blood cell adherence but missed by gel testing can cause hemolytic transfusion reactions. *Transfusion*, *56*(12), 2973-2979.

Harmening DM. Modern Blood Banking & Transfusion Practices. 5th ed. Philadelphia: F.A. Davis Company; 2005.

O'Brien P, Hopkins L, McCarthy D, Murphy S (1998). Complement-binding anti-Jka not detectable by DiaMed gels. *Vox Sanguinis*, 74(1), 53-55.

Reid ME, Lomas-Francis, C, Olsson ML. The Blood Group Antigen FactsBook. 3<sup>rd</sup> ed. Elsevier Ltd; 2012.

Stratton F (1956). The Value of Fresh Serum in the Detection and Use of Anti-Jka Antibody. *Vox Sanguinis*, 1:160-166.

Villa MA, Moulds M, Coluccio EB, Pizzo MN, Paccapel C, Revelli, N, Morelati F, Truglio F, Manera MC, Tedeschi A, Marconi M (2007). An acute haemolytic transfusion reaction due to anti-Jka. *Blood Transfusion*, *5*(2), 102-106.











#### **DOES THE ANTIGEN TYPING SUPPORT THE RESULTS?**

	Anti-Jk <sup>a</sup>
Pos	2+ <sup>s</sup>
Neg	0
Patient Cells	1+ <sup>mf</sup>



- O Pos
- Screening Cells II & III both 2+ (Gel)
- Negative DAT
- Patient multiply transfused 8 days previously
- Client is requesting antibody identification and 4 units of RBCs to have available for AM surgery













# DENSITY GRADIENT CELL SEPARATION

Washed PRBCs into microhct tubes

- ≥ 3 days since transfusion
- Sample <24 hours old
- Mix continuously while filling tubes

Centrifuge for 15 minutes

- This method will only be effective if patient is producing reticulocytes
- Cells containing Hgb S are not effectively separated by this method

Cut tube 5mm below the top of the column of cells  Newly formed autologous red cells generally have a lower specific gravity than transfused red cells and will therefore concentrate at the top of the column of red cells when blood is centrifuged in a microhematocrit tube











## WHAT DO THE RETICS TELL US?

	Anti-Jk <sup>a</sup>
Pos	2+ <sup>s</sup>
Neg	0
Whole Blood	1+ <sup>mf</sup>
Patient Reticulocytes	(0)



#### What we know so far:

- O Positive
- Positive DAT
- Anti-Jk<sup>a</sup> in plasma, retics type Jk(a-)











## **WAIT...WHAT ABOUT CELL #5?**

				Rh			K	ell	Du	Duffy		Kidd		M	NS		Results		
		D	С	E	С	е	К	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jka	Jkb	M	N	S	S	5 min RT	PEG IAT	
1	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	+	0	0	+	0	+	0	+	0	+	0	(0) 🗸	
2	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	(0) 🗸	
3	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	0	0	+	0	+	0	0	0	(0) ✓	
4	rr	0	0	0	+	+	0	+	0	0	0	+	+	0	0	+	S	(0) 🗸	
5	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	0	+	+	0	+	+	0	(+ <sup>w</sup> )	
6	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	+	0	0	+	0	+	0	(0) 🗸	
7	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	+	0	0	+	0	+	0	+	0	(0) 🗸	
8	rr	0	0	0	+	+	0	+	+	+	0	+	+	0	+	0	0	(0) 🗸	
Aut o																	0	(0) 🗸	











# HLA ANTIBODY OR ANTIBODY TO LOW INCIDENCE ANTIGEN?

- Suspect when only one/two cells reactive
- All common specificities have been excluded



- Resolution:
  - EGA treat reactive cells
  - Test selective cells positive for low incidence antigens
  - Consider dosage or carryover of cold reactive antibody; evaluate reactivity at RT & 4C
  - Treat reactive cells with DTT, trypsin and/or ficin and repeat testing











## **WAIT...WHAT ABOUT CELL #5?**

		Rh									_				-				
				Rh			K	ell	Du	Duffy		dd		M	NS			Results	1
		P	C	E	С	e	К	k	Fy <sup>a</sup>	ξVp	Jk <sup>a</sup>	<b>J</b> k <sup>b</sup>	M	N	S	S	5 min RT	PEG IAT	EGA PEG IAT
1	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	+	0	0	+	0	+	0	+	0	+	0	(0) 🗸	/
2	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	(0) 🗸	/
3	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	0	0	+	0	+	0	0	0	(0) 🗸	/
4	rr	0	0	0	+	+	0	+	0	0	0	+	+	0	0	+	0	(0) 🗸	/
5	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	0	+	+	0	+	+	0	(+ <sup>w</sup> )	(0) 🗸
6	R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	+	0	0	+	0	+	0	(0) 🗸	/
7	$R_1R_1$	+	+	0	0	+	0	+	+	0	0	+	0	+	0	+	0	(0) 🗸	1
8	rr	0	0	0	+	+	0	+	+	+	0	+	+	0	+	0	0	(0) 🗸	1
Auto																	0	(0) 🗸	/











# **OUR WORKUP - ELUATE**

#### **Direct Antiglobulin Test**

Poly	IgG	C,	Saline
(+) <sup>mf</sup>	(+w)mf	(0)	(0)

				Rh			K	ell	Duffy		Kidd		MNS				Results
		X	\ <u>\</u>	X.	\C\	\e\	K	\\	lya/	¥γ	1ka	<b>Vk</b> b∕	M	N	\S\	S/	PEG IAT
1	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	0	+	0	+	0	+	0	+	(0) 🗸
2	$R_0R_0$	+	0	+	+	0	0	+	0	+	+	0	+	+	+	0	(0) 🗸
3	rr	0	0	0	+	+	+	+	0	+	+	0	+	0	+	0	(0) 🗸
4	$R_1R_1$	+	+	0	0	+	0	+	+	0	+	0	+	0	0	+	(0) 🗸
5	rr	0	0	0	+	+	0	+	+	0	+	0	0	+	0	+	(0) 🗸
6	$R_1R_1$	+	+	0	0	+	0	+	+	+	+	+	+	0	0	+	(0) 🗸
7	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	+	+	+	0	+	0	0	+	0	+	(0) 🗸
8	rr	0	0	0	+	+	+	+	0	+	0	+	0	+	0	+	(0) 🗸











# FINAL REPORT

- O Pos
- Positive DAT (IgG): Cause unknown
- Eluate: No alloantibodies detected
- Plasma: Anti-Jka, patient's retics type Jk(a-)
- Plasma: HLA antibody
- Transfusion recommendation:
  - Jk(a-)
  - Donor blood should be nonreactive with patient's plasma
- Sent 4 O Pos, Jk(a-) LRPC that were nonreactive with patient's plasma











# 3 DAYS LATER...



Client requested 4 additional O Pos, Jk(a-) units for surgery.











# 7 DAYS LATER...

- Client submitted sample for antibody identification and has requested 2 units STAT
- Patient has received a total of 13 Red Cell transfusions, the most recent being 2 days prior to specimen collection
- All samples submitted are hemolyzed













# **WORKUP #2 – ABORH & DAT**

		ABO Group			Rh	Туре
	Anti-A	Anti-B	A <sub>1</sub> Cells	B Cells	Anti-D	Control
IS	0	0	4+	4+	2+ <sup>mf</sup>	0



#### **Direct Antiglobulin Test**

Poly	IgG	C'	Saiine
	(+)		(0)











# **WORKUP #2 – 1<sup>ST</sup> PANEL**

		1	Rh				Kell		Duffy		Kidd		MNS				Results	
		D	С	E	X	X	К	k	Fya	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk⁵	X	N	S	\ \ \	5 min RT	PEG IAT
1	$R_1R_1$	+	+	0	0	+	+	+	0	+	0	+	+	+	+	0	0	(+)
2	rr	0	0	0	+	+	0	+	+	+	0	+	+	0	+	0	0	(0) 🗸
3	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	+	0	0	+	+	0	+	+	0	1+
4	$R_1R_1$	+	+	0	0	+	+	0	0	+	0	+	0	+	0	+	0	1+
5	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	1+
6	R <sub>2</sub> r'	+	+	+	0	+	0	+	+	0	0	+	+	0	0	+	0	(+)
7	rr	0	0	0	+	+	0	+	+	0	0	+	+	0	0	+	0	(0) 🗸
Auto																	0	(+)

#### History of anti-Jk<sup>a</sup> and HLA antibody











# **WORKUP #2 – 2<sup>ND</sup> PANEL**

			Rh			Kell		Duffy		Kidd			M	NS		Results	
		D	X	X	X	e	X	X	Fya	Eyb	Jkª	¥kb∕	M	X	S	X5	PEG IAT
1	$R_1R_1$	+	+	0	0	+	0	+	+	0	0	+	+	0	+	+	(+)
2	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	+	0	0	+	+	0	+	+	1+
3	r'r	0	+	0	+	+	0	+	0	+	0	+	0	+	+	+	(0) 🗸
4	rr	0	0	0	+	+	0	+	0	+	0	+	+	+	0	+	(0) 🗸
5	rr	0	0	0	+	0	0	+	+	0	0	+	0	+	0	+	(0) 🗸
6	rr	0	0	0	+	+	+	+	+	+	0	+	+	0	+	+	(0) 🗸
7	rr	0	0	0	+	+	0	+	+	+	0	+	+	0	+	0	(0) 🗸
8	rr	0	0	0	+	+	+	+	0	+	0	+	+	+	+	+	(0) 🗸
9	r'r'	0	+	0	0	+	+	+	+	+	0	+	0	+	0	+	(0) 🗸
10	r'r'	0	+	0	0	+	0	+	+	+	0	+	+	0	+	+	(0) 🗸
11	r"r"	0	0	+	+	0	0	+	+	+	0	+	+	+	0	+	(0) 🗸
12	r"r"	0	0	+	+	0	0	+	0	+	0	+	+	0	0	+	(0) 🗸











#### **WORKUP #2 - ELUATE**

#### **Direct Antiglobulin Test**

Poly	lgG	C,	Saline
(0)	(+)	(0)	(0)

		V	Rh				K	Kell		Duffy		Kidd		M	Results		
		D	X	X	X	X	X	X	Ty	X	Jk³	M	X	X	X	X	PEG IAT
1	$R_1R_1$	+	+	0	0	+	0	+	+	0	0	+	+	0	+	+	(+)
2	$R_0R_0$	+	0	0	+	+	0	+	+	0	0	+	+	+	+	0	(+)
3	rr	0	0	0	+	+	0	+	+	+	+	0	+	0	+	0	(0) 🗸
4	rr	0	0	0	+	+	+	+	0	+	0	+	+	+	+	+	(0) 🗸
5	rr	0	0	0	+	+	+	+	+	0	0	+	0	+	0	+	(0) 🗸
6	rr	0	0	0	+	+	0	+	+	+	+	0	+	0	+	0	(0) 🗸
7	R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	+	0	0	+	+	0	+	+	1+
8	rr	0	0	0	+	+	0	+	+	0	0	+	0	+	0	+	(0) 🗸
9	r'r'	0	+	0	0	+	+	+	+	+	0	+	0	+	0	+	(0) 🗸
10	r'r'	0	+	0	0	+	0	+	+	+	0	+	+	0	+	+	(0) 🗸
11	r"r"	0	0	+	+	0	0	+	+	+	0	+	+	+	0	+	(0) 🗸
12	r"r"	0	0	+	+	0	0	+	0	+	0	+	+	0	0	+	(0) 🗸
























# **WORKUP CONCLUSIONS**

- Appears as if there is anti-D in the eluate & plasma
- Patient has historically been O Positive
- Is the anti-D autoantibody or alloantibody?
  - Partial D perhaps?











# TIME FOR SOME INVESTIGATING

		Rh	Туре			
	Anti-A	Anti-B	A <sub>1</sub> Cells	B Cells	Anti-D	Control
IS	0	0	4+	4+	2+mf	0

Anti-D
r <sup>mf</sup>
The same of the sa













### **LET'S TRY TO GET SOME MORE INFO...**



- 1. Contacted facility requesting workup:
  - Patient urgently transfused 2 O+ & 1 O- RBCs during LifeFlight to facility
  - Patient's cells typed weakly with anti-D (1+w), reported as O Positive
  - Obtained facility information where patient was originally treated
- 2. Contacted facility where patient was 1st treated:
- ABORh: O Negative
- Negative antibody screen
- Transfused 2 O+ & 1 O- RBCs during LifeFlight to transfer facility











# FINAL REPORT

ABORh: O NEGATIVE

DAT: Positive (IgG)

Plasma & Eluate: Anti-D

- Previously identified anti-Jk<sup>a</sup> & HLA antibody
- Transfusion Recommendation:
  - D-negative
  - Jk(a-)
  - Nonreactive with the patient's plasma (HLA)
- Sent 2 D-negative, C-negative, E-negative, Jk(a-) units prior to completion of workup for emergency use in surgery











## "Unity is strength... when there is teamwork and collaboration, wonderful things can be achieved."

### Mattie Stepanek













### REFERENCES

Fung MK, Eder AF, Spitalnik SL, Westhoff CM. Technical Manual. 19<sup>th</sup> ed. Bathesda, Maryland: AABB; 2017.

Harmening DM. Modern Blood Banking & Transfusion Practices. 5th ed. Philadelphia: F.A. Davis Company; 2005.

Kay B, Poisson JL, Tuma CW, Shulman IA (2016). Anti-Jk<sup>a</sup> that are detected by solid-phase red blood cell adherence but missed by gel testing can cause hemolytic transfusion reactions. *Transfusion*, *56*(12), 2973-2979.

O'Brien P, Hopkins L, McCarthy D, Murphy S (1998). Complement-binding anti-Jka not detectable by DiaMed gels. *Vox Sanguinis*, 74(1), 53-55.

Reid ME, Lomas-Francis, C, Olsson ML. The Blood Group Antigen FactsBook. 3<sup>rd</sup> ed. Elsevier Ltd; 2012.

Stratton F (1956). The Value of Fresh Serum in the Detection and Use of Anti-Jka Antibody. *Vox Sanguinis*, 1:160-166.

Villa MA, Moulds M, Coluccio EB, Pizzo MN, Paccapel C, Revelli, N, Morelati F, Truglio F, Manera MC, Tedeschi A, Marconi M (2007). An acute haemolytic transfusion reaction due to anti-Jka. *Blood Transfusion*, *5*(2), 102-106.











# **QUESTIONS???**

